REG - Genedrive PLC - Block listing Interim Review

GenedriveAnnouncement

30/11/2023 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231130:nRSd2920Va&default-theme=true

RNS Number : 2920V  Genedrive PLC  30 November 2023

 

genedrive plc

("genedrive" or the "Company")

 

Block Listing Returns

 

The Company confirms the block listing six monthly return for the period to 30
November 2023.

 

 Name of applicant                                                               genedrive plc

 Name of scheme                                                                  2007 Share Option Scheme

 Period of return:                       From:                                   01 June 2023  To:         30 November 2023
 Balance of unallocated securities under scheme(s) from previous return:         131,726 shares

 Plus: The amount by which the block scheme(s) has been increased since the      Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period       Nil
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:      131,726 shares

 

 Name of applicant                                                               genedrive plc

 Name of scheme                                                                  2017 Share Option Scheme

 Period of return:                       From:                                   01 June 2023  To:         30 November 2023
 Balance of unallocated securities under scheme(s) from previous return:         1,150,588 shares

 Plus: The amount by which the block scheme(s) has been increased since the      Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period       Nil
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:      1,150,588 shares

 

 Name of applicant                                                               genedrive plc

 Name of scheme                                                                  Unapproved Share Option Scheme

 Period of return:                       From:                                   01 June 2023  To:           30 November 2023
 Balance of unallocated securities under scheme(s) from previous return:         2,668,144 shares

 Plus: The amount by which the block scheme(s) has been increased since the      Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period       Nil
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:      2,668,144 shares

 Name of contact:                                                                Russ Shaw CFO
 Telephone number of contact:                                                    +44 (0)161 989 0245

 

For enquires:

 

 

 

 genedrive plc                                       +44 (0)161 989 0245
 James Cheek: CEO / Russ Shaw: CFO

 Peel Hunt LLP (Nominated Adviser and Joint Broker)  +44 (0)20 7418 8900
 James Steel / Patrick Birkholm

 Walbrook PR Ltd (Media & Investor Relations)        +44 (0)20 7933 8780 or genedrive@walbrookpr.com
                                                     (mailto:genedrive@walbrookpr.com)
 Anna Dunphy                                         +44 (0)7876 741 001

 

About genedrive plc (http://www.genedriveplc.com
(http://www.genedriveplc.com/) )

 

genedrive plc is a pharmacogenetic testing company developing and
commercialising a low cost, rapid, versatile, simple to use and robust point
of need pharmacogenetic platform for the diagnosis of genetic variations. This
helps clinicians to quickly access key genetic information that will help them
make the right choices over the right medicine or dosage to use for an
effective treatment. Based in the UK, the Company is at the forefront of work
on Point of Care pharmacogenetics. Pharmacogenetics looks at how your genetics
impacts a medicines ability to work for you. Therefore by using
pharmacogenetics, medicines can be made safer and more effective. The Company
has launched its flagship product, the Genedrive® MT-RNR1 ID Kit, which is a
single-use disposable cartridge which circumvents the requirement for cold
chain logistics by providing temperature stable reagent test kits for use on
their proprietary test platform. This test allows clinicians to make a
decision on antibiotic use within 26 minutes, ensuring vital care is delivered
with no negative impact on the patient pathway.

 

The Company has a clear commercial strategy focused on accelerating growth
through maximising in-market sales, geographic and portfolio expansion and
strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRURUBROWUAOAA